Literature DB >> 24366915

Bioresorbable scaffolds: rationale, current status, challenges, and future.

Javaid Iqbal1, Yoshinobu Onuma, John Ormiston, Alexandre Abizaid, Ron Waksman, Patrick Serruys.   

Abstract

Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, and neoatherosclerosis. The permanent stents also indefinitely impair the physiological vasomotor function of the vessel and future potential of grafting the stented segment. Bioresorbable scaffolds (BRSs) have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. While a number of BRSs are under development, two devices with substantial clinical data have already received a Conformité Européenne marking. This review article presents the current status of these devices and evaluates the challenges that need to be overcome before BRSs can become the workhorse device in coronary intervention.

Entities:  

Keywords:  Bioresorbable scaffolds; Coronary angioplasty; Drug-eluting stents

Mesh:

Substances:

Year:  2013        PMID: 24366915     DOI: 10.1093/eurheartj/eht542

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  50 in total

1.  How far have we come with bioresorbable vascular scaffolds, and where should we go?

Authors:  Jeehoon Kang; Kyung Woo Park; Hyo Soo Kim
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 2.  Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease.

Authors:  Bhargav Dave
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  Crimping-induced structural gradients explain the lasting strength of poly l-lactide bioresorbable vascular scaffolds during hydrolysis.

Authors:  Karthik Ramachandran; Tiziana Di Luccio; Artemis Ailianou; Mary Beth Kossuth; James P Oberhauser; Julia A Kornfield
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-17       Impact factor: 11.205

4.  Bioresorbable Scaffolds in Spontaneous Coronary Artery Dissection: Long-Term Follow-Up in 4 Patients.

Authors:  Santiago Jesús Camacho Freire; Antonio Enrique Gómez Menchero; Jessica Roa Garrido; Javier León Jiménez; Rosa Cardenal Piris; José Francisco Díaz Fernández
Journal:  Tex Heart Inst J       Date:  2017-12-19

5.  Bioresorbable scaffold-the holy grail of percutaneous coronary intervention: fact or myth?

Authors:  Kevin Liou; Nigel Jepson
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

6.  Bioresorbable drug eluting scaffolds-are bioresorbable stents ready for today's clinical practice?

Authors:  Christoph Lutter; Michael Joner
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

7.  A Combination of Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in the Treatment of Multivessel Coronary Artery Disease.

Authors:  Ahmed Al-Mamary; Filippo Zilio; Massimo Napodano
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

8.  Very late bioresorbable vascular scaffold thrombosis at 25 months post implantation.

Authors:  Koo Hui Chan; Swee-Chong Seow; Huay Cheem Tan
Journal:  Singapore Med J       Date:  2017-09       Impact factor: 1.858

9.  Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens.

Authors:  Athanasios Katsikis; Patrick W Serruys
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

10.  Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.

Authors:  Florian Blachutzik; Niklas Boeder; Jens Wiebe; Alessio Mattesini; Oliver Dörr; Astrid Most; Timm Bauer; Jens Röther; Monique Tröbs; Christian Schlundt; Stephan Achenbach; Christian W Hamm; Holger M Nef
Journal:  Clin Res Cardiol       Date:  2016-10-18       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.